Enrique Conterno

Type: Person
Name: Enrique Conterno
First reported Aug 20 2014 - Updated Aug 20 2014 - 2 reports

Lilly, Boehringer Ingelheim Get Tentative FDA OK For Basaglar

By Estel Grace MasangkayEli Lilly together with its partner Boehringer Ingelheim announced that the U.S. Food and Drug Administration (FDA) has granted tentative approval to Basaglar (insulin glargine injection) indicated for the improvement of glycemic ... [Published Bioresearch Online - Aug 20 2014]
First reported Aug 20 2014 - Updated Aug 20 2014 - 1 reports

Boehringer and Eli Lilly receive FDA approval for type 2 diabetes drug

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company have received the FDA approval for Jardiance tablets as an adjunct to diet and exercise to improve glycemic control, or blood glucose levels, in adults with type 2 diabetes, or T2D. ... [Published Individual.com - Aug 20 2014]
First reported Aug 18 2014 - Updated Aug 19 2014 - 2 reports

Lilly and Boehringer Ingelheim's Basaglar granted tentative approval

INDIANAPOLIS and RIDGEFIELD, Conn. — The Food and Drug Administration has granted tentative approval for Basaglar (insulin glargine injection), which is used to improve glycemic control in adults with Type 2 diabetes and in combination with mealtime insulin ... [Published Drug Store News - Aug 19 2014]
First reported Aug 18 2014 - Updated Aug 19 2014 - 4 reports

Tentative FDA approval for Lilly and Boehringer Ingelheim's Basaglar

The US Food and Drug Administration yesterday granted tentative approval for Basaglar (insulin glargine injection), which is indicated to improve glycemic control in adults with type 2 diabetes and in combination with mealtime insulin in adults and pediatric ... [Published Pharma Letter - Aug 19 2014]
First reported Aug 18 2014 - Updated Aug 18 2014 - 1 reports

FDA approves Jardiance empagliflozin tablets for adults with type 2 diabetes

By a News Reporter-Staff News Editor at Clinical Trials Week Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company (NYSE: LLY) announced the U.S. Food and Drug Administration (FDA) approved Jardiance (empagliflozin) tablets as an ... [Published Pharmacy Choice - Aug 18 2014]
First reported Aug 14 2014 - Updated Aug 14 2014 - 1 reports

Drug Approvals & Updates, Licensing Agreements, and Upcoming Conferences - Research Reports on Tekmira, MannKind, Eli Lilly, GSK and Cigna

/PRNewswire/ --Today, Analysts Review released its research reports regarding Tekmira Pharmaceuticals Corp. ( NASDAQ: TKMR ), MannKind Corp. ( NASDAQ: MNKD ), Eli Lilly and Company ( NYSE: LLY ), GlaxoSmithKline PLC ( NYSE: GSK ) and Cigna Corp. ( NYSE: ... [Published Securities Technology Monitor - Aug 14 2014]
First reported Aug 13 2014 - Updated Aug 13 2014 - 1 reports

Eli Lilly : FDA approves Jardiance® empagliflozin tablets for adults with type 2 diabetes

By a News Reporter-Staff News Editor at Clinical Trials Week -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company (NYSE: LLY) announced the U.S. Food and Drug Administration (FDA) approved Jardiance® (empagliflozin) tablets as ... [Published 4 Traders - Aug 13 2014]
First reported Aug 11 2014 - Updated Aug 11 2014 - 1 reports

FDA approves ]ardiance® tablets for adults with type 2 diabetes

RIDGEFIELD, Conn., and INDIANAPOLIS— (BIPI) and have announced that the approved Jardiance· (empagliflozin) tablets as an adjunct to diet and exercise to improve glycemic control, or blood glucose levels, in adults with type 2 diabetes (T2D). Jardiance ... [Published Drug Discovery News - Aug 11 2014]
First reported Aug 07 2014 - Updated Aug 07 2014 - 1 reports

FDA OKs Jardiance Tablets

Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company reported the U.S. Food and Drug Administration approved Jardiance tablets as an adjunct to diet and exercise to improve glycemic control, or blood glucose levels, in adults with type 2 diabetes. ... [Published Individual.com - Aug 07 2014]
First reported Aug 04 2014 - Updated Aug 05 2014 - 1 reports

BI-Lilly Diabetes gets OK for Jardiance

RIDGEFIELD, Conn., and INDIANAPOLIS – Eli Lilly & Co. and Boehringer Ingelheim Pharmaceuticals Inc. have been cleared by the Food and Drug Administration to market Jardiance tablets (empagliflozin), a treatment for type 2 diabetes.The companies said that ... [Published Chain Drug Review - Aug 04 2014]
First reported Aug 02 2014 - Updated Aug 02 2014 - 1 reports

US FDA approves Jardiance for adults with type 2 diabetes

The US Food and Drug Administration on Friday approved Jardiance (empagliflozin) tablets as an adjunct to diet and exercise to improve glycemic control, or blood glucose levels, in adults with type 2 diabetes (T2D).The drug, which was recently approved ... [Published Pharma Letter - Aug 02 2014]
First reported Jun 30 2014 - Updated Jun 30 2014 - 1 reports

CHMP recommends Lilly/Boehringer's new insulin glargine product for approval in EU to treat type 1 and type 2 diabete

The Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending approval for the investigational compound LY2963016, a new insulin glargine product, for the treatment of type 1 and type 2 diabetes. The new insulin glargine ... [Published PharmaBiz - Jun 30 2014]

More Content

All (26) | News (26) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Lilly, Boehringer Ingelheim Get Tentative FDA O... [Published Bioresearch Online - Aug 20 2014]
Basaglar Receives Tentative FDA Approval for Di... [Published Pharmacy Times - Aug 20 2014]
Boehringer and Eli Lilly receive FDA approval f... [Published Individual.com - Aug 20 2014]
Eli Lilly wins tentative OK for basal insulin [Published Indianapolis Star - Aug 19 2014]
Lilly and Boehringer Ingelheim's Basaglar grant... [Published Drug Store News - Aug 19 2014]
Tentative FDA approval for Lilly and Boehringer... [Published Pharma Letter - Aug 19 2014]
FDA Tentatively Approves Lilly/Boehringer Ingel... [Published Pharmaceutical Manufacturing Magazine - Aug 19 2014]
‘Tentative’ US approval for Lilly/Boehringer’s ... [Published PMLive - Aug 19 2014]
Lilly grabs a "tentative" FDA OK for insulin tr... [Published FierceBiotech - Aug 19 2014]
Lilly and Boehringer Ingelheim's Basaglar (insu... [Published News-Medical.Net - Aug 19 2014]
'Tentative' US OK for Lilly/BI's Basaglar [Published Pharma Times - Aug 18 2014]
FDA Grants Tentative Approval for Lilly and Boe... [Published Nasdaq - Aug 18 2014]
FDA Grants Tentative Approval for Lilly and Boe... [Published PredictWallStreet - Aug 18 2014]
FDA approves Jardiance empagliflozin tablets fo... [Published Pharmacy Choice - Aug 18 2014]
Drug Approvals & Updates, Licensing Agreements,... [Published Securities Technology Monitor - Aug 14 2014]
Eli Lilly : FDA approves Jardiance® empaglifloz... [Published 4 Traders - Aug 13 2014]
FDA approves ]ardiance® tablets for adults with... [Published Drug Discovery News - Aug 11 2014]
FDA OKs Jardiance Tablets [Published Individual.com - Aug 07 2014]
US FDA approves Jardiance tablets for adults wi... [Published PharmaBiz - Aug 05 2014]
BI-Lilly Diabetes gets OK for Jardiance [Published Chain Drug Review - Aug 04 2014]
FDA Approves Jardiance For Type 2 Diabetes [Published Bidness Etc - Aug 04 2014]
US FDA approves Jardiance for adults with type ... [Published Pharma Letter - Aug 02 2014]
Eli Lilly's (LLY) CEO John Lechleiter on Q2 201... [Published Seeking Alpha - Jul 25 2014]
CHMP recommends Lilly/Boehringer's new insulin ... [Published PharmaBiz - Jun 30 2014]
EU grants marketing approval for Jardiance tabs... [Published PharmaBiz - May 24 2014]
Lilly's phase III trial for once-weekly dulaglu... [Published PharmaBiz - Feb 27 2014]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.